This website uses its own and third-party cookies in order to improve the browsing experience. If you continue browsing you will be accepting expressly the use of these cookies. You can get more information on our Cookies policy page.



BIOLAN HEALTH has developed a rapid serological test for the detection of antibodies against SARS-CoV-2, the virus that causes COVID-19.

A new serological test to detect IgG and IgM antibodies against SARS-CoV-2 has been developed by BIOLAN HEALTH. The test is quick and easy to use, from a drop of capillary blood, will allow identify people who are or have been infected by the virus that causes COVID-19.
A very differentiating feature of the BIOLAN HEALTH test is that it allows the detection of antibodies directed against the SARS-CoV-2 zone responsible for the entry of the virus into the cell, the receptor binding region (RBD) of the Spike-1 protein. These antibodies that target the RBD have the potential to be neutralizers against SARS-CoV-2 and therefore may prevent future infections. Therefore, the new serological test of BIOLAN HEALTH, will allow to identify persons who have neutralising antibodies against SARS-CoV-2 and therefore can be "potentially" immune.
This means that, in addition to being a useful tool for carrying out epidemiological studies to gain a better understanding of the incidence and spread of the virus, it can also be a very useful tool for assessing the effectiveness of vaccines.
BIOLAN HEALTH will be in charge of their manufacture, for which it has set up a specific production line that will soon be complete with all the necessary equipment, as shown in the following report: